Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Mogrosides for Delayed-Onset Muscle Soreness

17 de setembro de 2026 atualizado por: Jingzhi Zhang, Guangxi Normal University

Effects of Mogroside Intervention on the Levels of Delayed-Onset Muscle Soreness-Related Indicators

This study will examine whether taking mogrosides, natural compounds found in monk fruit, affects delayed-onset muscle soreness (DOMS) and related markers of muscle damage, inflammation, oxidative stress, and muscle function after strenuous exercise. The study will also explore whether changes in the body's antioxidant capacity are related to changes in DOMS-related measures.

The study plans to enroll 16 healthy young male students. Participants will be randomly assigned to a control group (n=8) or an experimental group (n=8). The control group will receive a placebo, and the experimental group will receive mogrosides. Participants will take their assigned product by mouth for 27 days, perform a standardized frog-jump training session, and then continue taking the assigned product for 3 more days.

Researchers will measure subjective muscle soreness using a visual analog scale (VAS) at baseline before supplementation, before exercise, immediately after exercise, and 24, 48, and 72 hours after exercise. At these same time points, they will also measure serum creatine kinase (CK) and creatine kinase isoenzyme MM (CK-MM) activity, total antioxidant capacity (T-AOC), malondialdehyde (MDA), plasma interleukin-6 (IL-6), thigh circumference at the junction of the middle and lower thirds of the thigh, maximal isometric strength for lifting the thigh, and active range of motion (AROM) of the knee.

The study will assess the effects of mogroside supplementation on DOMS severity and on changes in muscle damage, inflammation, oxidative stress, and muscle function. It will also explore whether improved antioxidant capacity is related to changes in DOMS-related indicators. This study is not yet recruiting participants.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

16

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Jingzhi Zhang
  • Número de telefone: +86 16677137704
  • E-mail: 170787717@qq.com

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

20 anos a 23 anos (Adulto)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Macho

Descrição

Inclusion Criteria:

  • Male, aged 20 to 23 years.
  • Healthy, with no history of major diseases or severe injuries.
  • Physical fitness level comparable to that of an ordinary physical education/sports student.
  • No training or competition obligations during the study period.
  • Provides informed consent for the study protocol.

Exclusion Criteria:

  • History of musculoskeletal injury within the past 2 months.
  • Use of anti-inflammatory drugs or steroid medications within the past 1 month.
  • Use of antioxidant medications such as vitamin E or vitamin C within the past 1 month.
  • Use of any other medications within the past 2 weeks.
  • Participation in strenuous exercise within the past 10 days.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Mogroside

Eight participants will be randomly assigned to the experimental arm. They will receive oral mogroside (batch no. YTC19011823; purity >95%; mogroside V 50.56%), prepared as a 3% (g/mL) solution in warm drinking water, at 6 g per dose twice daily (12 g/day) in the morning and evening for 27 days. After 27 days, participants will perform a standardized frog-jump exercise to induce delayed-onset muscle soreness (DOMS): 10 sets of 25 consecutive jumps, with 2 minutes of rest between sets, after a 10-minute warm-up; total session approximately 34-35 minutes. They will continue the same mogroside intervention for 3 additional days after exercise. All participants will complete the same scheduled assessments. The study will be double-blind.

Eight participants will be randomly assigned to the experimental arm. They will receive oral mogroside (batch no. YTC19011823; purity >95%; mogroside V 50.56%), prepared as a 3% (g/mL) solution in warm drinking water, at 6 g per dose twice daily (12 g/day) in the morning and evening for 27 days. After 27 days, participants will perform a standardized frog-jump exercise to induce delayed-onset muscle soreness (DOMS): 10 sets of 25 consecutive jumps, with 2 minutes of rest between sets, after a 10-minute warm-up; total session approximately 34-35 minutes. They will continue the same mogroside intervention for 3 additional days after exercise. All participants will complete the same scheduled assessments. The study will be double-blind.

Comparador de Placebo: Placebo

Eight participants will be randomly assigned to the control arm. They will receive an equal volume of warm drinking water as placebo twice daily in the morning and evening for 27 days. After 27 days, participants will perform the same standardized frog-jump exercise to induce delayed-onset muscle soreness (DOMS): 10 sets of 25 consecutive jumps, with 2 minutes of rest between sets, after a 10-minute warm-up; total session approximately 34-35 minutes. They will continue the same placebo intervention for 3 additional days after exercise. All participants will complete the same scheduled assessments. The study will be double-blind.

Eight participants will be randomly assigned to the control arm. They will receive an equal volume of warm drinking water as placebo twice daily in the morning and evening for 27 days. After 27 days, participants will perform the same standardized frog-jump exercise to induce delayed-onset muscle soreness (DOMS): 10 sets of 25 consecutive jumps, with 2 minutes of rest between sets, after a 10-minute warm-up; total session approximately 34-35 minutes. They will continue the same placebo intervention for 3 additional days after exercise. All participants will complete the same scheduled assessments. The study will be double-blind.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Muscle Soreness Assessed by Visual Analog Scale (VAS)
Prazo: From enrollment to the end of treatment at 30 days

Subjective muscle soreness will be assessed at six time points: before the first dose of study product, before exercise, immediately after exercise, and 24, 48, and 72 hours after exercise. A 10-cm VAS ruler will be used. The side facing the participant is marked 0 at one end ("no pain") and 10 at the other ("worst imaginable pain"). Participants will move a cursor to indicate their current level of muscle soreness. The distance from the "no pain" end to the mark will be recorded as the pain score in centimeters. Higher scores indicate greater muscle soreness.

From enrollment to the end of treatment at 30 days

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Active Range of Motion (AROM) of the Knee
Prazo: From enrollment to the end of treatment at 30 days

Bilateral active knee range of motion will be measured with a joint angle goniometer at six time points: before the first dose, before exercise, immediately after exercise, and 24, 48, and 72 hours after exercise. Participants will lie prone with both lower limbs extended, together, and relaxed. The goniometer axis will be placed at the lateral femoral condyle, the fixed arm along the middle of the femur, and the moving arm along the fibula. Participants will actively flex the lower leg as much as possible. The arc from the starting position to the final position of the lower leg will be recorded in degrees.

From enrollment to the end of treatment at 30 days
Maximal Isometric Muscle Force for Lifting the Thigh
Prazo: From enrollment to the end of treatment at 30 days

Bilateral maximal isometric muscle force will be measured with a MicroFET2 handheld dynamometer at six time points: before the first dose, before exercise, immediately after exercise, and 24, 48, and 72 hours after exercise. Participants will sit on the examination bed with arms at their sides, legs relaxed, and lower legs hanging vertically. The tester will place the dynamometer over the distal quadriceps on the front of the thigh. Participants will push the thigh upward against the tester and maintain the contraction for 8 seconds. The test will be repeated 5 times, and the maximum value will be recorded.

From enrollment to the end of treatment at 30 days
Thigh Circumference at the Junction of the Middle and Lower Thirds
Prazo: From enrollment to the end of treatment at 30 days

Bilateral thigh circumference will be measured with a soft tape measure at six time points: before the first dose, before exercise, immediately after exercise, and 24, 48, and 72 hours after exercise. Participants will lie prone on the examination bed. The circumference will be measured at the junction of the middle and lower thirds of the line between the greater trochanter of the femur and the lateral condyle. The measurement point will be marked after the first measurement to ensure the same location is used at later time points. Results will be recorded in centimeters.

From enrollment to the end of treatment at 30 days

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

19 de setembro de 2026

Conclusão Primária (Estimado)

1 de novembro de 2026

Conclusão do estudo (Estimado)

1 de novembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

17 de setembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

17 de setembro de 2026

Primeira postagem (Real)

23 de setembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

23 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

17 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • GXNU20260903003

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .